CN104906179A - Origanum oil suspension and preparation method thereof - Google Patents
Origanum oil suspension and preparation method thereof Download PDFInfo
- Publication number
- CN104906179A CN104906179A CN201510151871.8A CN201510151871A CN104906179A CN 104906179 A CN104906179 A CN 104906179A CN 201510151871 A CN201510151871 A CN 201510151871A CN 104906179 A CN104906179 A CN 104906179A
- Authority
- CN
- China
- Prior art keywords
- herba origani
- origani oil
- suspensoid
- suspending agent
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of a medicine used for livestock and poultry, and concretely relates to an origanum oil suspension and a preparation method thereof. The origanum oil suspension comprises the following components by mass percentage: A)greater than or equal to 2% and less than or equal to 30% of origanum oil, B) greater than or equal to 0.5% and less than or equal to 10% of surfactant, C) greater than or equal to 0.2% and less than or equal to 1% of suspending agent, D) greater than or equal to 0.1% and less than or equal to 1% of antiseptic, and E)balance of injection water. The preparation method comprises the following steps: 1)uniformly mixing the surfactant, the antiseptic and origanum oil; 2)uniformly mixing the suspending agent and 30 times amount of injection water or completely dissolving; and 3)mixing the solutions obtained in the step 1) and step 2), adding the injection water to 100% to obtain a mixed liquor, and placing in a mixer for rapidly stirring for 30 minutes at speed of 2000r/m to obtain the origanum oil suspension.
Description
Technical field
The present invention relates to poultry with medicament field, specifically, relate to a kind of Herba Origani oil suspensoid and preparation method thereof.
Background technology
Herba Origani oil is a kind of vegetable active oil extracted in plant Adeps Bovis seu Bubali, the effect of anti-inflammation is played by contact pathogenic microorganism, action intensity is proportional with its concentration to a certain extent, namely contact surface is larger, bactericidal effect is stronger, for a kind of antimicrobial drug of low-toxicity green environment-friendly type, but it is insoluble in water and majority of organic solvent.
The Ministry of Agriculture of China " import veterinary medical quality standard " (version in 1999) is recorded, and Herba Origani oil is used for the treatment of grice enteritidis diarrhoea.At present, commercially see and produce the dosage form of use, only have oil solution and the powder of Herba Origani oil, and Herba Origani oil Emulsion (as CN102920781A), the oil solution preparation of Herba Origani oil has not easily absorption and catharsis effect, contradicts with its action function; And Herba Origani oil powder belongs to coarse dispersion system, Herba Origani oil is adsorbed on carrier, exists with graininess, and be difficult to absorb, pharmacological action is restricted; And the antioxidant oxidation-reduction potential in Herba Origani oil Emulsion (as CN102920781A) is than the height of Herba Origani oil, antioxidation can not be played, and its formulation cost is higher.For many years, the Herba Origani oil solution of market a kind of stable, low cost of demand always, but still lack corresponding formula and technology.
Summary of the invention
In order to solve problems of the prior art, the object of this invention is to provide a kind of Herba Origani oil suspensoid and preparation method thereof.
In order to realize the object of the invention, first the present invention provides a kind of Herba Origani oil suspensoid, and it is prepared from by the component of following mass percent:
A, 2≤Herba Origani oil≤30%
B, 0.5%≤surfactant≤10%
C, 0.2%≤suspending agent≤1%
D, 0.1%≤antiseptic≤1%
E, surplus are water for injection.
Further, described surfactant is Tweens and/or spans.
Further, described suspending agent is modification soluble cellulose class.
As preferably, described suspending agent be carmellose and or carmethose.
Further, described antiseptic is aldehydes matter, preferred phenol.
Further, the preparation process of described Herba Origani oil suspensoid is as follows:
1) surfactant, antiseptic are mixed homogeneously with Herba Origani oil, for subsequent use;
2) suspending agent mixed homogeneously with the water for injection of 30 times amount or dissolve completely, for subsequent use;
3) by step 1) with step 2) solution that obtains mixes, injects water to 100% and obtain mixed liquor, be placed in blender with 2000 revs/min of rapid stirrings 30 minutes, obtain Herba Origani oil suspensoid.
Present invention also offers a kind of preparation method of Herba Origani oil suspensoid, described Herba Origani oil suspensoid is prepared from by the component of following mass percent:
A, 2% < Herba Origani oil≤30%
B, 0.5%≤surfactant≤10%
C, 0.2%≤suspending agent≤1%
D, 0.1%≤antiseptic≤1%
E, surplus are water for injection;
Described method specifically comprises the steps:
1) surfactant, antiseptic are mixed homogeneously with Herba Origani oil, for subsequent use;
2) suspending agent added the water for injection mix homogeneously of 30 times amount or dissolve completely, for subsequent use;
3) by step 1) with step 2) solution that obtains mixes, injects water to 100% and obtain mixed liquor, be placed in blender with 2000 revs/min of rapid stirrings 30 minutes, obtain Herba Origani oil suspensoid.
As preferably, described Herba Origani oil suspensoid is prepared from by the component of following percentage by weight:
A, 2% < Herba Origani oil≤30%
B, 0.5%≤surfactant≤10%
C, 0.2%≤suspending agent≤1%
D, 0.1%≤antiseptic≤0.5%
E, surplus are water for injection.
Further, described surfactant is Tweens and/or spans.
As preferably, described suspending agent is selected from carboxymethyl cellulose class.
Beneficial effect of the present invention is:
Herba Origani oil component disperses in Herba Origani oil suspensoid provided by the present invention becomes microfine, and surface area becomes geometric proportion to strengthen, and fully can contact, play bactericidal action to greatest extent with pathogenic microorganism.The main dispersion medium of described Herba Origani oil suspensoid is water for injection, wide material sources, low price.Described surfactant can promote the contact of Herba Origani oil and pathogenic microorganism, strengthens the bactericidal effect of Herba Origani oil.Described antiseptic be phenol both can play antisepsis can also Wheat Protein.In addition, because the effect of active component Herba Origani oil is not fully exerted, bioavailability is greatly improved, thus reduces the consumption of Herba Origani oil, not only increases drug effect, also a saving cost.
Detailed description of the invention
Following examples for illustration of the present invention, but are not used for limiting the scope of the invention.
Embodiment 1
1, formula:
Above-mentioned each composition is commercially available product.
2, technique:
(1) Tween 80, phenol are mixed homogeneously with Herba Origani oil, for subsequent use;
(2) microcrystalline Cellulose mixed homogeneously with the water for injection of 30 times amount or dissolve completely, for subsequent use;
(3) by above-mentioned two liquid mixing, the amount of 100% is injected water to, then rapid stirring 30 minutes in the blender this mixed liquor being put 2000 revs/min, namely obtain uniform and stable suspensoid.
3, the content detecting Herba Origani oil is the 2.25-2.75% of labelled amount.
4, subpackage, sealing, print bag.
Embodiment 2
1, formula:
Above-mentioned each composition is commercially available finished product.
2, technique:
(1) sorbester p18, phenol are mixed homogeneously with Herba Origani oil, for subsequent use;
(2) microcrystalline Cellulose mixed homogeneously with the water for injection of 30 times amount or dissolve completely, for subsequent use;
(3) by above-mentioned two liquid mixing, the amount of 100% is injected water to, then rapid stirring 30 minutes in the blender this mixed liquor being put 2000 revs/min, namely obtain uniform and stable suspensoid.
3, the content detecting Herba Origani oil is the 2.25-2.75% of labelled amount.
4, subpackage, sealing, print bag.
Embodiment 3
1, formula:
Above-mentioned each composition is commercially available finished product.
2, technique:
(1) Tween 80, phenol are mixed homogeneously with Herba Origani oil, for subsequent use;
(2) sodium carboxymethyl cellulose mixed homogeneously with the water for injection of 30 times amount or dissolve completely, for subsequent use;
(3) by above-mentioned two liquid mixing, the amount of 100% is injected water to, then rapid stirring 30 minutes in the blender this mixed liquor being put 2000 revs/min, namely obtain uniform and stable suspensoid.
3, the content detecting Herba Origani oil is the 2.25-2.75% of labelled amount.
4, subpackage, sealing, print bag.
Embodiment 4
1, formula:
Above-mentioned each composition is commercially available finished product.
2, technique:
(1) Tween 80, phenol are mixed homogeneously with Herba Origani oil, for subsequent use;
(2) by the water for injection heating for dissolving of sodium carboxymethyl cellulose and 30 times amount, then mix homogeneously with appropriate water for injection, for subsequent use;
(3) by above-mentioned two liquid mixing, the amount of 100% is injected water to, then rapid stirring 30 minutes in the blender this mixed liquor being put 2000 revs/min, namely obtain uniform and stable suspensoid.
3, the content detecting Herba Origani oil is the 2.25-2.75% of labelled amount.
4, subpackage, sealing, print bag.
Embodiment 5
1, formula:
Above-mentioned each composition is commercially available finished product.
2, technique:
(1) Tween 80, phenol are mixed homogeneously with Herba Origani oil, for subsequent use;
(2) water for injection of sodium carboxymethyl cellulose and 30 times amount is heated to dissolve completely, adds glycerol, for subsequent use;
(3) by above-mentioned two liquid mixing, the amount of 100% is injected water to, then rapid stirring 30 minutes in the blender this mixed liquor being put 2000 revs/min, namely obtain uniform and stable suspensoid.
3, the content detecting Herba Origani oil is the 2.25-2.75% of labelled amount.
4, subpackage, sealing, print bag.
The effect of experimental example 1 Herba Origani oil suspensoid clinical trial treatment yellow and white dysentery of piglet and chicken colibacillosis
1, test objective
In order to verify the drug effect of Herba Origani oil suspensoid provided by the invention, this experimental example utilizes Herba Origani oil suspensoid provided by the invention and control formulation to carry out the therapeutic test of HUANGBAI(sic) dysentery to piglet and chicken respectively and chicken colibacillosis is tested.Test data gathers according to testing program in batches.
2, test material
2.1 use medicine
2.1.1 trial drug 1: the Herba Origani oil suspensoid that embodiment 5 is obtained.
2.1.2 contrast medicament 2: certain company produce 10% Herba Origani oil pre-mixing agent.
2.1.3 chlortetracycline 3: the chlortetracycline raw material that certain company produces.
2.2 experimental animal and grouping
2.2.1 delivery room, pig farm, Xiangtan County newborn piglet 386, about 7 ages in days, wherein has 127 to occur drawing yellow scours, listless, is off one's feed.Select at random wherein 7 as blank group, all the other 120 pigs are divided into 3 groups (trial drug group, control drug group, chlortetracycline matched groups) at random, often organize 40.
2.2.2, in Hengyang City's chicken house, 329 plumages in the chicken about 10 ages in days, are had to occur drawing Hakuri, listless, the situation of being off one's feed.Random selecting 20 plumage is as blank group, and all the other 309 plumages are divided into three groups (trial drug group, control drug group, chlortetracycline matched groups) at random, often organize 103 plumages.
3, test method
3.1 trial drug treated animals are labeled as A group, the preparation obtained by embodiment 5, every 100L water, and pig is added 100mL chicken and adds 100mL.
3.2 control drug treated animals are labeled as B group, and by feedstuff per ton, pig adds 200g; Chicken adds 250g.
3.3 chlortetracycline matched groups are labeled as C, and pig, chicken all add 100g by feedstuff per ton.
3.4 blank assay group echos are D group, only give chow diet, do not add any medicine.
The equal continuous use of above-mentioned experimental animal 7 days, observes 5 days again after medication, observes clinical symptoms and death condition every day, cut open inspection to animals died of illness.Calculate the effective percentage of each test group, cure rate, Relapse rate situation.
3.5 criterion
3.5.1 effective percentage: clinical symptom relief (diarrhoea stop or alleviating, spirit take a turn for the better, appetite increase etc.)
3.5.2 cure rate: clinical symptom disappearance (diarrhoea stops, and spirit takes a turn for the better, appetite recovery is normal) in 5 days after drug withdrawal.
3.5.3 Relapse rate: after drug withdrawal, in 5 days, clinical symptoms increases the weight of or death.
3.5.4 inefficiency: unchanged or increase the weight of or dead or disease relapse in duration of test (after comprising drug withdrawal in 5 days) clinical symptoms.
4, result of the test
The therapeutic outcome of 4.1 pairs of yellow and white dysentery of piglet is in table 1.
The therapeutic outcome of table 1 yellow and white dysentery of piglet compares
| Group | Piglet head number | Dead head number | Head number repeatedly | Cure head number | Effective percentage | Inefficiency |
| A | 40 | 2 | 0 | 38 | 95％ | 5％ |
| B | 40 | 3 | 3 | 34 | 85％ | 15％ |
| C | 40 | 7 | 6 | 27 | 67.5％ | 32.5％ |
| D | 7 | 6 | 0 | 0 | 14.3％ | 100％ |
The therapeutic outcome of 4.2 pairs of chicken colibacillosis is in table 2.
The therapeutic outcome of table 2 chicken colibacillosis compares
| Group | Chicken plumage number | Dead plumage number | Plumage number repeatedly | Cure plumage number | Effective percentage | Inefficiency |
| A | 103 | 8 | 2 | 93 | 90.3％ | 9.7％ |
| B | 103 | 12 | 3 | 88 | 85.4％ | 14.6％ |
| C | 103 | 15 | 6 | 82 | 79.6％ | 20.4％ |
| D | 20 | 18 | 1 | 1 | 5％ | 95％ |
5, test result analysis and conclusion
5.1 as can be seen from above-mentioned result of the test, and comparatively matched group medicine is better for total therapeutic effect of Herba Origani oil suspensoid.
5.1.1 Herba Origani oil suspensoid treatment yellow and white dysentery of piglet effect is better than than contrast group medicine, significant difference.Chlortetracycline group therapeutic effect is not fine, may be to cause because produce drug resistance.The cure rate of Herba Origani oil pre-mixing agent also reaches more than 80%, illustrates that this cause of disease is more responsive to Herba Origani oil.
5.1.2 Herba Origani oil suspensoid treatment chicken colibacillosis effect is better than matched group medicine, and significant difference.The same therapeutic effect of chlortetracycline group is unsatisfactory.
5.2 Herba Origani oil suspensoids of the present invention all can reach desirable therapeutic effect by mixing to raise or be watered to feed to the poultry such as piglet, chicken.
5.3 Herba Origani oil suspensoids of the present invention are better than conventional chlortetracycline effect of drugs to the common bacterial disease effect of animal, can substitute chlortetracycline completely, and have no side effect, noresidue.
Experimental example 2 Herba Origani oil suspendible stability test
Three batches of finished products that this experimental example obtains for embodiment 5, carried out stability study according to Ministry of Agriculture's " veterinary drug stability test technical specification (trying) " to it, object is to check Herba Origani oil suspensoid provided by the invention to light, heat, wet stability.
1. materials and methods
1.1 main agents
Methanol (chromatographically pure) Beijing chemical reagents corporation
Ethanol (color is said pure) Beijing chemical reagents corporation
Acetonitrile (chromatographically pure) Beijing chemical reagents corporation
Glacial acetic acid (chromatographically pure) Beijing chemical reagents corporation
Hydrochloric acid (chemical analysis is pure) Beijing chemical reagents corporation
Herba Origani oil reference substance (content 50.98%) China Veterinary Drugs Supervisory Inst.
Embodiment 5 Herba Origani oil suspension
1.2 key instrument
High performance liquid chromatograph (HPLC) LC-10A Japan Shimadzu
Xin Hua paper mill, qualitative filter paper middling speed Q/ZHJ3017-91 Hangzhou
CX-100 ultrasonic cleaner Beijing armarium two factory
Precision acidity meter (PHS-3C) Shanghai Lei Ci instrument plant
2XZ-1 type rotary-vane vaccum pump Jinggong Vacuum Equipment Plant, Linhai City
BP310S trace semimicro-analy-tical balance, Sartorius company of BP211D analytical balance Germany
The automatic dual pure water distillator Shanghai glass apparatus company of D1810C
Instrucment and meter plant of JD-3 type illumination meter Shanghai International Automobile City Tourist Festival student's federation
Huangshi medical apparatus and instruments factory of water isolation type electro-heating standing-temperature cultivator GSP-781 type Hubei Province
The detection method of content of Herba Origani oil in 1.3 said preparations
Detect with reference to Ministry of Agriculture's quality standard
1.4 acceleration by light tests
By the obtained three batches of Herba Origani oil suspensions of embodiment 5, represent with No. 1, No. 2, No. 3 respectively, obtained each finished product is loaded in colourless airtight plastic bottle, putting illumination is place 10 days under the condition of 4500 ± 500LX, respectively at 0,5,10 day timing sampling, the indexs such as working sample character, suspension ability, content.
1.5 heating and moistening tests
According to " Ministry of Agriculture's veterinary drug stability techniques specification (trying) ", determine that this preparation should be 30 ± 2 DEG C in temperature, relative humidity is carry out heating and moistening test under the condition of 60 ± 5%.Sodium nitrite saturated solution is adopted to be humidizer, be placed in bottom exsiccator, the sample of each three batches of three kinds of specifications is placed in the upper strata of exsiccator, put into water isolation type electro-heating standing-temperature cultivator in the lump, temperature regulating to 30 ± 2 DEG C, monthly sample once, routine observation 6 months, the indexs such as working sample character, suspension ability, content.
2, results and analysis
2.1 acceleration by light tests
Respectively acceleration by light test is carried out to three batches of formulation samples, the results are shown in Table 3.In table, result shows, said preparation was 4500 ± 500LX strong illumination 10 days, and suspension ability, content, character have no significant change.
Table 3 acceleration by light result of the test
2.2 heating and moistening tests
By three batches of homemade preparations, after plastic bottle sealing, carry out heating and moistening test, have no significant change at 1 month, 2 months, 3 months, 4 months, 5 months, 6 months its appearance luster, suspension ability, content, result shows, this compound preparation is to heating and moistening good stability.The results are shown in Table 4.
Table 4 is heated accelerated test result for six months
3, brief summary and discussion
The requirement of this experimental evidence Ministry of Agriculture in 1999 No. 13 files " veterinary drug stability test technical specification (trying) ", under the condition of intense light irradiation, investigates the project such as content, appearance character, suspension ability, the uniformity of said preparation.Result of the test shows, test 10 days in acceleration by light, indices meets the requirements, and illustrates that this preparation is relatively stable to illumination.
The requirement of this experimental evidence Ministry of Agriculture in 1999 No. 13 files " veterinary drug stability test technical specification (trying) ", under the condition of high temperature, high humility, investigates the project such as content, appearance character, content, the uniformity of said preparation.Result of the test shows, at 6 the end of month of heating and moistening stability test, the appearance luster of preparation significant change does not occur, all the other indices are normally, meet the requirement of " People's Republic of China's veterinary drug allusion quotation ", therefore, the environment of high humidity, high heat is still stable.
In sum, Herba Origani oil suspensoid provided by the present invention to light, heat, wet be all stable.
Although above the present invention is described in detail with a general description of the specific embodiments, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (10)
1. a Herba Origani oil suspensoid, is characterized in that, it is prepared from by the component of following mass percent:
A, 2≤Herba Origani oil≤30%
B, 0.5%≤surfactant≤10%
C, 0.2%≤suspending agent≤1%
D, 0.1%≤antiseptic≤1%
E, surplus are water for injection.
2. Herba Origani oil suspensoid according to claim 1, is characterized in that, described surfactant is Tweens and/or spans.
3. Herba Origani oil suspensoid according to claim 1 and 2, is characterized in that, described suspending agent is modification soluble cellulose class.
4. Herba Origani oil suspensoid according to claim 3, is characterized in that, described suspending agent be carmellose and or carmethose.
5. Herba Origani oil suspensoid according to claim 3, is characterized in that, described antiseptic is aldehydes matter, preferred phenol.
6. Herba Origani oil suspensoid according to claim 5, is characterized in that, the preparation process of described Herba Origani oil suspensoid is as follows:
1) surfactant, antiseptic are mixed homogeneously with Herba Origani oil, for subsequent use;
2) suspending agent mixed homogeneously with the water for injection of 30 times amount or dissolve completely, for subsequent use;
3) by step 1) with step 2) solution that obtains mixes, injects water to 100% and obtain mixed liquor, be placed in blender with 2000 revs/min of rapid stirrings 30 minutes, obtain Herba Origani oil suspensoid.
7. a preparation method for Herba Origani oil suspensoid, is characterized in that, described Herba Origani oil suspensoid is prepared from by the component of following mass percent:
A, 2% < Herba Origani oil≤30%
B, 0.5%≤surfactant≤10%
C, 0.2%≤suspending agent≤1%
D, 0.1%≤antiseptic≤1%
E, surplus are water for injection;
Described method specifically comprises the steps:
1) surfactant, antiseptic are mixed homogeneously with Herba Origani oil, for subsequent use;
2) suspending agent added the water for injection mix homogeneously of 30 times amount or dissolve completely, for subsequent use;
3) by step 1) with step 2) solution that obtains mixes, injects water to 100% and obtain mixed liquor, be placed in blender with 2000 revs/min of rapid stirrings 30 minutes, obtain Herba Origani oil suspensoid.
8. method according to claim 7, is characterized in that, described Herba Origani oil suspensoid is prepared from by the component of following percentage by weight:
A, 2% < Herba Origani oil≤30%
B, 0.5%≤surfactant≤10%
C, 0.2%≤suspending agent≤1%
D, 0.1%≤antiseptic≤0.5%
E, surplus are water for injection.
9. the method according to claim 7 or 8, is characterized in that, described surfactant is Tweens and/or spans.
10. method according to claim 9, is characterized in that, described suspending agent is selected from carboxymethyl cellulose class.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510151871.8A CN104906179A (en) | 2015-04-01 | 2015-04-01 | Origanum oil suspension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510151871.8A CN104906179A (en) | 2015-04-01 | 2015-04-01 | Origanum oil suspension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104906179A true CN104906179A (en) | 2015-09-16 |
Family
ID=54075896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510151871.8A Pending CN104906179A (en) | 2015-04-01 | 2015-04-01 | Origanum oil suspension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104906179A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106804983A (en) * | 2017-03-14 | 2017-06-09 | 安徽标王农牧有限公司 | A kind of 1 to 35 day compound complete feed of Huaibei partridge chicken brood time |
| CN108498583A (en) * | 2018-05-29 | 2018-09-07 | 中国水产科学研究院黄海水产研究所 | A kind of composition and application method of prevention Penaeus Vannmei bacteriosis |
| CN113425676A (en) * | 2021-07-07 | 2021-09-24 | 河北农业大学 | Oregano macleaya cordata oral solution and preparation method thereof |
| CN117581868A (en) * | 2023-11-24 | 2024-02-23 | 湖南农业大学 | Bactericide for preventing and treating kiwi fruit canker and citrus canker and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973646A (en) * | 2012-12-14 | 2013-03-20 | 江苏恒丰强生物技术有限公司 | Origanum oil oral emulsion and preparation method thereof |
-
2015
- 2015-04-01 CN CN201510151871.8A patent/CN104906179A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102973646A (en) * | 2012-12-14 | 2013-03-20 | 江苏恒丰强生物技术有限公司 | Origanum oil oral emulsion and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106804983A (en) * | 2017-03-14 | 2017-06-09 | 安徽标王农牧有限公司 | A kind of 1 to 35 day compound complete feed of Huaibei partridge chicken brood time |
| CN108498583A (en) * | 2018-05-29 | 2018-09-07 | 中国水产科学研究院黄海水产研究所 | A kind of composition and application method of prevention Penaeus Vannmei bacteriosis |
| CN108498583B (en) * | 2018-05-29 | 2020-12-15 | 中国水产科学研究院黄海水产研究所 | Composition for preventing and treating bacterial diseases of penaeus vannamei boone and use method thereof |
| CN113425676A (en) * | 2021-07-07 | 2021-09-24 | 河北农业大学 | Oregano macleaya cordata oral solution and preparation method thereof |
| CN117581868A (en) * | 2023-11-24 | 2024-02-23 | 湖南农业大学 | Bactericide for preventing and treating kiwi fruit canker and citrus canker and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bueno et al. | A new approach for in vitro bioassay to measure tannin biological effects based on a gas production technique | |
| CN104906179A (en) | Origanum oil suspension and preparation method thereof | |
| CN105726522B (en) | Magnolol is killing application and its preparation in fish parasitic protozoa | |
| CN104940147B (en) | A kind of Tilmicosin pre-mixing agent and preparation method thereof | |
| CN107496361A (en) | A kind of thyme essential oil solid dispersions and preparation method thereof | |
| CN102908313A (en) | Veterinary albendazole suspension and preparation method thereof | |
| CN104906121A (en) | Tildipirosin-containing medicinal composition | |
| CN105193709A (en) | Enrofloxacin injection and preparation method thereof | |
| CN101439083B (en) | Detection method of Chinese medicine soft capsules for clearing wind heat and clearing nasal passage | |
| CN104173600B (en) | Four taste Herba Andrographitis dissipate solid dispersions and preparation method thereof | |
| CN104906039B (en) | A kind of Tilmicosin suspension and preparation method thereof | |
| CN105125484A (en) | Painless doxycycline injection and preparation method thereof | |
| CN111297808B (en) | Darlinomycin hydrochloride soluble powder capable of being directly dissolved in oil seedlings and preparation method thereof | |
| CN109172599A (en) | Microcapsule formulation and preparation method thereof for preventing and treating chicken leucocyte protozoon | |
| CN103983735A (en) | Detection method for preparing Gongyanping (brand) capsules | |
| CN103417552B (en) | General quinoline-sulfamethoxazole compound injection and the preparation method of ending for animals | |
| CN105943541A (en) | Long-acting breast injection agent for treating cow mastitis in dry period and preparation method of long-acting breast injection agent | |
| CN109223710A (en) | Molecule micro emulsion and preparation method thereof for preventing and treating chicken leucocyte protozoon | |
| CN101574355B (en) | Compound antibacterial injection for livestock and preparation method thereof | |
| CN102908354A (en) | Preparation method of butafosfan injection | |
| CN109497287A (en) | A kind of feed addictive can promote growth of animal | |
| CN111529521A (en) | Chinese herbal medicine feed biological additive, biological feed and preparation method | |
| CN102813625A (en) | Preparation method of tartaric acid valnemulin premixing agent | |
| CN108077579A (en) | A kind of Chinese herbal feed additive for improving livestock and poultry production performance and its preparation method and application | |
| CN101933901A (en) | Mixed suspension injection liquid containing tylosin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150916 |